Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 2/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16884266 | 0.79 | KDM4E (0.36) | CNR2HDAC6KDM4EALDH1A1MEN1 | |
| SCHEMBL3360337 | 0.75 | CNR2 (0.46) | CNR2EPHX2HDAC6KDM4EALDH1A1 | |
| SCHEMBL15009152 | 0.74 | ALDH1A1 (0.44) | CNR2EPHX2HDAC6KDM4EALDH1A1 | |
| SCHEMBL16887740 | 0.72 | CNR2 (0.40) | CNR2EPHX2HDAC6KDM4EALDH1A1 | |
| SCHEMBL23977808 | 0.72 | CNR2 (0.42) | CNR2EPHX2HDAC6KDM4EALDH1A1 | |
| SCHEMBL15009200 | 0.72 | MEN1 (0.49) | CNR2EPHX2HDAC6KDM4EALDH1A1 | |
| SCHEMBL15029047 | 0.72 | HDAC6 (0.48) | CNR2EPHX2HDAC6KDM4EALDH1A1 | |
| SCHEMBL16884352 | 0.71 | EPHX2 (0.44) | CNR2EPHX2HDAC6KDM4EALDH1A1 | |
| SCHEMBL15013412 | 0.71 | ALDH1A1 (0.38) | CNR2HDAC6KDM4EALDH1A1MEN1 | |
| SCHEMBL16884203 | 0.71 | SLC2A1 (0.42) | CNR2KDM4EALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884832-B2 | Inhibitors targeting drug-resistant influenza A | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-02-06 | — | — | US | disclosed |
| US-20150191439-A1 | INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191439-A1 | INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A | HAVCR2, HDLBP, HSP90B1 | CNR2 4661/4885EPHX2 4332/4885HDAC6 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.